fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Saphnelo approved in the US for moderate to severe systemic lupus erythematosus – AstraZeneca

Written by | 10 Aug 2021

AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy…. read more.

Aerobic exercise may mildly delay, slightly improve Alzheimer’s symptoms

Written by | 10 Aug 2021

Alzheimer’s disease (AD) is a brain disorder that destroys memory and thinking skills over time. It is the most common form of dementia in older adults. There is… read more.

FDA approves Keytruda to treat high-risk early-stage triple-negative breast cancer – Merck Inc.

Written by | 9 Aug 2021

Merck Inc. announced that the FDA has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy… read more.

Cutting 250 calories daily and exercising may improve heart health in obese older adults

Written by | 9 Aug 2021

Cutting just 250 calories a day with moderate exercise reaped bigger rewards than exercise alone for older, obese adults. Among older adults with obesity, combining aerobic exercise with… read more.

Kyowa Kirin provides update on application for istradefylline in Europe for the treatment of ‘OFF’ episodes in people livingwith Parkinson’s

Written by | 8 Aug 2021

Kyowa Kirin Co., Ltd. has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an… read more.

Scientists identify severe asthma species, show air pollutant as likely contributor

Written by | 8 Aug 2021

Asthma afflicts more than 300 million people worldwide. The most severe manifestation, known as non-Th2, or non-atopic childhood asthma, represents the majority of the cases, greater than 85%,… read more.

FDA approves Octapharma’s octagam 10% for adult dermatomyositis

Written by | 7 Aug 2021

The FDA has granted approval to Octapharma USA for Octagam 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment… read more.

Synthetic hinge could hold key to revolutionary ‘smart’ insulin therapy

Written by | 7 Aug 2021

For people with diabetes who are insulin dependent, glycemic control is a full-time job. But what if their medication could do the work for them — an insulin… read more.

Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia after second dose for COVID-19 – AstraZeneca

Written by | 6 Aug 2021

Rates of the very rare clotting disorder, thrombosis with thrombocytopenia syndrome (TTS), following a second dose of Vaxzevria are comparable to the background rate in an unvaccinated population… read more.

Acne in adult women – impact on quality of life

Written by | 6 Aug 2021

Acne is often viewed as a disease of adolescence but for many women it persists into adulthood. In a qualitative study of 50 adult women with acne, participants… read more.

Aspirin lowers cardiovascular events in pneumonia patients

Written by | 5 Aug 2021

Aspirin appears to reduce cardiovascular events in patients with pneumonia, researchers reported on July 7, 2021 at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Investigator… read more.

Cognitive decline linked to bone loss and fracture risk

Written by | 5 Aug 2021

New research carried out under the auspices of the Canadian Multicentre Osteoporosis Study (CaMos) has found that cognitive decline is linked with accelerated bone loss and an increased… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.